ActualitésAssisté par IA

Biomerica Appoints Eric B. Chin To Board Of Directors, Chair Of Audit Committee

Biomerica appoints Eric B. Chin to Board, replacing Cathy Coste and strengthening financial leadership.

Simantini Singh Deo
Par Simantini Singh Deo
Rédacteur principal de contenu
7 juin 2025Updated Jun 26, 2025 · 2 min de lecture
Biomerica Appoints Eric B. Chin To Board Of Directors, Chair Of Audit Committee
Journalisme assisté par IA
Reviewed by Simantini Singh Deo, Rédacteur principal de contenu

Biomerica, Inc., a global biomedical company specializing in diagnostic and therapeutic products, has appointed Eric B. Chin to its Board of Directors, effective June 4, 2025. Mr. Chin will serve as Chairperson of the Audit Committee and as a member of both the Nominating and Corporate Governance Committee and the Compensation Committee.

Mr. Chin is a seasoned financial executive with deep expertise in healthcare and life sciences. He is currently CFO of Akido Labs, a healthcare technology firm emphasizing preventive care, where he recently played a key role in raising $60 million in funding. In addition to his CFO role, Mr. Chin serves as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation. His prior experience includes leadership roles at Astrana Health, Public Storage, and Alexandria Real Estate Equities, and he began his career at Ernst & Young. He is also a Certified Public Accountant.

Mr. Chin succeeds Ms. Cathy Coste, who stepped down from the board on June 4, 2025. Biomerica clarified that her resignation was not due to any disagreement with the company’s operations or governance.

Simantini Singh Deo
Written by
Simantini Singh Deo
Rédacteur principal de contenu

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.

Discussion

Chargement de la discussion…

Plus dans Pharma News

Tous les articles →